1 / 13

Aarkstore Market Research Report - Frontier Pharma Prostate

The prostate cancer pipeline is among the largest in the pharmaceutical industry with 484 products in active development across all stages. For More Details: http://goo.gl/cIMtf5

addyparker2350
Télécharger la présentation

Aarkstore Market Research Report - Frontier Pharma Prostate

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Aarkstore Market Research Report - Frontier Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class Innovation To buy this Report Visit http://www.aarkstore.com

  2. Discounted Market Research Reports available on Aarkstore.com Offer valid till 28th February, 2015 • For more inquiries, contact at +91 9987295242 / 022-27564953 • Email: enquiry@aarkstore.com To buy this Report Visit http://www.aarkstore.com

  3. Summary  Exceptionally Large and Innovative Pipeline The prostate cancer pipeline is among the largest in the pharmaceutical industry with 484 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations in this pipeline is exceptional; GBI Research analysis identified 174 first-in-class programs in the prostate cancer pipeline, acting on 122 first-in-class molecular targets. This accounts for some 36% of all products with a disclosed molecular target and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as, despite the high attrition rate in prostate cancer, it is highly likely many of the first-in-class technologies will reach the market over the coming decade and may transform the clinical and commercial landscape.

  4. Summary Alignment of First-in-Class Molecular Target with Disease Causation  One of the key trends in oncology and in prostate cancer in particular over the last decade is the clinical and commercial impact of targeted therapies designed to target proteins in signaling pathways that are strongly associated with disease progression. By aligning the molecular targets for therapeutic intervention with disease causation and/or propagation, these therapies limit the systemic cytotoxic effects whilst inhibiting tumor-promoting signaling pathways. Such strategies thereby typically achieve superior efficacy and safety profiles.

  5. Summary A Deals Landscape with Numerous Investment OpportunitiesAnalysis has confirmed that 169 of the 174 first-in-class products have not been involved in a licensing or co-development deal. Although many act on targets that are not yet strongly substantiated in terms of their therapeutic potential in prostate cancer in clinical studies, there are many which are supported by promising in vivo and in vitro preclinical evidence, and as such are highly promising prostate cancer therapies. Indeed, breakthrough innovations are highly desirable as an investment option.

  6. Scope The report analyzes innovation in prostate cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzed the deals landscape surrounding first-in-class products in prostate cancer, and pinpoints opportunities for in-licensing. The report covers and includes -  - A brief introduction to prostate cancer, including symptoms, pathophysiology, and overview of pharmacotherapy and treatment algorithms. - The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline. - Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target. - Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets. - Assessment of the licensing and co-development deal landscape for prostate cancer therapies and benchmarking of deals involving first-in-class versus non-first-in-class-products.

  7. Reasons To Buy The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to -  - Understanding of the focal shifts in molecular targets in the prostate cancer pipeline. - Understanding of the distribution of pipeline programs by phase of development, molecule type and molecular target. - Access a scientific and clinical analysis of first-in-class developmental programs for prostate cancer, benchmarked against non-first-in-class targets. - Access a list of the first-in-class therapies potentially open to deal-making opportunities To know more about this report click here: http://www.aarkstore.com/pharmaceuticals-healthcare/87810/frontier-pharma-prostate-cancer-identifying-and-commercializing-first-in-class-innovation

  8. Table of Contents Frontier Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class Innovation Executive Summary Clinical and Commercial Landscape Assessment of Pipeline Product Innovation First-in-Class Target and Pipeline Program

  9. Price Chart Frontier Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class Innovation Product Price : Click Here To View OR Purchase Report:

  10. Related Market Research Report • Generic Drugs Market in Japan 2015-2019 • Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Metastatic Brain Tumor-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Lupus Erythematosus-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Metastatic Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Malaria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  11. Metastatic Colorectal Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Melanoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Meningitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Pharmaceuticals & Healthcare Market Research Reports

  12. About Aarkstore Enterprise • Aarkstore Enterprise provides Industry and Market Analysis and Research Report with expertise and technology knowledge on business improvement and market acquisition. • Aarkstore achieved its debut pad in the year 2008 to explore, work on assignments and cater worldwide clients and business giants with business research on trends, markets and technologies. The latest set of applications guarantees active analysis and Market Research understanding for budding enterpriser and consultants to relate industry ground research.

  13. Contact Us Office Office No. - 809, 8th Floor, B-Wing, Mahaavir Icon,  Plot No.- 89 & 90, Sector-15, CBD-Belapur, Navi Mumbai – 400614,  Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit : http://www.aarkstore.com OR Mail us at : contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news

More Related